



Office: 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Telephone no.: 011-27355742, 71239900(44 Lines), CIN: L74999RJ1992PLC013387

To,

30.05.2026

Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

Dear Sir,

Sub: Outcome of Meeting of the Board of Directors of Titan Biotech Limited (the Company) held on May 30, 2026

In terms of the requirements of Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circulars, as amended from time to time, this is to inform you that the Board of Directors at its meeting held today, i.e. Saturday, May 30, 2026, has, *inter- alia*:

A. Approved the Audited Financial Results For The Financial Year Ended March 31, 2026

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the audited financial results of the Company, along with Auditors' Reports issued by the Statutory Auditors, on consolidated as well as standalone basis, for the quarter and year ended March 31, 2026, as reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held today i.e. May 30, 2026.

B. Recommendation Of Dividend

The Board of Directors has recommended a dividend of Rs. 0.50 (Fifty Paise Only) per equity share which is subject to approval of shareholders in the ensuing Annual General Meeting. The said dividend, if declared at the ensuing Annual General Meeting, will be credited/dispatched to the eligible shareholders after the AGM within the limit as prescribed under the Companies Act, 2013 and other applicable laws.

Information regarding Book closure/ Record date and dividend payment date will be informed in due course of time.

C. Approved the Re-appointment of Cost Auditor

The Board of Directors has approved the re-appointment of Cost Auditor, based on the recommendation of the Audit Committee:

M/s Sanjay Kumar Garg & Associates, Cost Accountants, (FRN-100292) as the Cost Auditor of the company subject to the ratification of remuneration by the shareholders at the ensuing AGM.

The disclosure pursuant to SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30th January, 2026, is enclosed as "**Annexure A**".



TITAN BIOTECH LIMITED

AN ISO 9001:2015 CERTIFIED COMPANY



Office: 903-909. 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Telephone no.: 011-27355742, 71239900(44 Lines), CIN: L74999RJ1992PLC013387

D. Appointment of Scrutinizer

Appointment of Mr. Pankaj Kumar Gupta (M. No: F6371, CP No: 19156), Practicing Company Secretary, as Scrutinizer of the Company to conduct and scrutinize the entire process of voting at the 34th Annual General Meeting of the Company to be held in 2026.

The meeting of Board of Directors commenced at **03:00 P.M. and concluded at 03:34 P.M.**

The above information will be available on the website of the company i.e www.titanbiotechltd.com and BSE Ltd i.e www.bseindia.com.

Request to kindly take this information on record and acknowledge.

**For and on behalf of
Titan Biotech Limited**



**Charanjit Singh
Company Secretary & Compliance Officer
M.No A12726**

Encl: As above



TITAN BIOTECH LIMITED

AN ISO 9001:2015 CERTIFIED COMPANY



Office: 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Telephone no.: 011-27355742, 71239900(44 Lines), CIN: L74999RJ1992PLC013387

Annexure-A

DISCLOSURE UNDER REGULATION 30 OF SEBI LISTING REGULATIONS READ WITH SEBI MASTER CIRCULAR ISSUED ON JULY 11, 2023 AND LAST UPDATED ON JANUARY 30, 2026 BEARING REFERENCE NO. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 ("SEBI CIRCULAR")

S.No	Particulars	Details
i.	Name of the Cost Auditor	M/s Sanjay Kumar Garg & Associates, Cost Accountants, Firm's Registration Number 100292
ii.	Reason for change viz re-appointment	Re-appointment as Cost Auditors of the Company
iii.	Date of Appointment & term of appointment	30-05-2026 for conducting Cost Audit of the Company for the F.Y 2026-2027
iv.	Brief Profile	Mr. Sanjay Kumar Garg (B.COM, FCMA (India), FIPA (Australia), FFA (Australia), CMA (USA), FloV, CIA) is Practicing Cost Accountant having Experience of more than 24 years in the field of Costing, Taxation, Auditing etc. Currently, He is President of IMA (Institute of Management Accountants) (USA) Delhi Chapter, India. He is also a member of Institute of Public Accountants (Australia), Institute of Financial Accountants (Australia), Certified Management Accountant of the Institute of Management Accountants, USA, Life Member of the Institute of Valuer (New Delhi), Member of Institute of Internal Auditor (Mumbai) and Member of Institute of Directors.
v.	Disclosure of relationships between director	Not Applicable



Independent Auditor's Review Report on Quarterly and year to date audited Standalone Financial Results of Titan Biotech Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

TO THE BOARD OF DIRECTORS OF TITAN BIOTECH LIMITED

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone financial results of Titan Biotech Limited (the company) for the quarter and year ended March 31, 2026 ("Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. Gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter and year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.



This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under 14(3)(i) of the Act, we are responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to standalone financial statements in place and operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The standalone annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year.

For A N S K & Associates,
Chartered Accountants
FRN - 026177N

AKHIL Digitally signed
by AKHIL MITTAL
MITTAL Date: 2026.05.30
13:49:19 +05'30'

(CA Akhil Mittal)
Partner
Membership No. – 517856
UDIN: 26517856SJKGJQ8777
Date: May 30, 2026
Place: Delhi

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2026

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	STANDALONE				
		QUARTER ENDED			YEAR ENDED	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
	AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED	
1	INCOME					
	Revenue from operations	4,883.35	5,650.57	3,516.93	20,619.03	15,645.08
	Other income	210.64	125.71	138.07	541.02	391.25
	Total income	5,093.99	5,776.28	3,655.00	21,160.05	16,036.33
2	EXPENSES					
	Cost of materials consumed	2,590.68	2,727.66	1,730.44	9,916.35	7,548.08
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(707.75)	9.12	(229.18)	(296.82)	(285.27)
	Employee benefits expense	943.53	853.09	694.39	3,236.20	2,637.96
	Finance costs	23.72	25.74	7.88	91.39	80.18
	Depreciation and amortization expense	129.75	126.63	84.33	492.53	416.98
	Other expenses	1,085.89	977.83	864.29	3,902.95	3,201.67
	Total expenses	4,065.82	4,720.07	3,152.15	17,342.60	13,599.60
3	Profit before exceptional items and tax (1-2)	1,028.17	1,056.21	502.85	3,817.45	2,436.73
4	Exceptional items	-	-	-	-	-
5	Profit before tax (3+4)	1,028.17	1,056.21	502.85	3,817.45	2,436.73
6	Tax expense					
	(I) Current tax	302.22	262.69	124.68	988.74	596.92
	(II) Deferred tax	70.38	6.70	1.56	83.99	12.40
	(III) Earlier year taxes	-	-	-	-	0.30
	Total tax (I+II+III)	372.60	269.39	126.24	1,072.73	609.62
7	Profit for the period (5-6)	655.57	786.82	376.61	2,744.72	1,827.11
8	Other comprehensive income					
	(i) Items that will not be reclassified to profit or loss					
A	(ia) Re-measurement gain on defined benefit plans	(19.51)	2.44	(7.76)	(12.19)	9.76
	(ii) Income tax on the above item	5.38	(0.61)	1.95	3.54	(2.46)
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax on the above item	-	-	-	-	-
	Total other comprehensive income for the period (A+B) (net of taxes)	(14.13)	1.83	(5.81)	(8.65)	7.30
9	Total comprehensive income for the period (7+8)	641.44	788.65	370.80	2,736.07	1,834.41
10	Paid-up equity share capital (face value of Rs. 2/- each)	826.37	826.37	826.37	826.37	826.37
11	Other Equity				16,257.78	13,686.99
12	Earnings per equity share (face value of Rs.2/- each) not annualised					
	(1) Basic	1.59	1.90	0.91	6.64	4.42
	(2) Diluted	1.59	1.90	0.91	6.64	4.42

Notes:

- The above audited standalone financial results for the quarter and year ended on 31.03.2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on May 30, 2026. The Statutory Auditors of the Company have been reviewed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015. The results for the quarter and year ended March 31, 2026, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com).
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31st March, 2026 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone audited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.
- During the year, the company paid Rs. 56.50 Lakhs towards Corporate Social Responsibility (CSR) expenditure.
- The subdivision of Equity Shares was made effective from 20th February, 2026, being the record date fixed for the subdivision of Equity Shares from existing Rs. 10/- per share to Rs. 2 per share in the ratio of 1:5. Consequently, the paid-up share capital of the company stands altered from 82,63,700 Equity Shares having a face value of Rs. 10/- each to 4,13,18,500 Equity Shares having face value Rs. 2/- each.
- The Board of Directors of the company has recommended a dividend of Rs. 0.50 per equity share for the financial year ended on 31st March, 2026. The Dividend will be paid after approval of the same by shareholders in the ensuing Annual General meeting.
- The Statutory Auditors have carried out audit of the financial results for the quarter and year ended on 31.03.2026 and have expressed an unmodified opinion in the audit report on these financial result.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED


NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place : Delhi
Dated : 30.05.2026

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2026

(Rs. IN LAKHS) except for EPS

Sr. No.	PARTICULARS	STANDALONE				
		QUARTER ENDED			YEAR ENDED	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
	AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED	
1	Total income from operations (Net)	5,093.99	5,776.28	3,655.00	21,160.05	16,036.33
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	1,028.17	1,056.21	502.85	3,817.45	2,436.73
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	1,028.17	1,056.21	502.85	3,817.45	2,436.73
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	655.57	786.82	376.61	2,744.72	1,827.11
5	Total comprehensive income for the period (comprising Profit for the period (after tax) and other comprehensive income(after tax)(refer note 3)	641.44	788.65	370.80	2,736.07	1,834.41
6	Paid-up equity share capital (Face value of Rs. 2/- per share)	826.37	826.37	826.37	826.37	826.37
7	Other equity excluding revaluation reserves as per the balance sheet	-	-	-	16,257.78	13,686.99
8	Earnings per share (of INR 2/- each)					
	(a) Basic	1.59	1.90	0.91	6.64	4.42
	(b) Diluted	1.59	1.90	0.91	6.64	4.42

NOTES :

- The above is an extract of the detailed format of standalone audited Financial Results for the quarter and year ended on 31.03.2026 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone audited Financial Results for the said quarter and year ended on 31.03.2026 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above audited standalone financial results for the quarter and year ended on 31.03.2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on May 30, 2026. The Statutory Auditors of the Company have been reviewed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015. The results for the quarter and year ended March 31, 2026, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com).
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31.03.2026 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone audited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.
- During the year, the company paid Rs. 56.50 Lakhs towards Corporate Social Responsibility (CSR) expenditure.
- The subdivision of Equity Shares was made effective from 20th February, 2026, being the record date fixed for the subdivision of Equity Shares from existing Rs. 10/- per share to Rs. 2 per share in the ratio of 1:5. Consequently, the paid-up share capital of the company stands altered from 82,63,700 Equity Shares having a face value of Rs. 10/- each to 4,13,18,500 Equity Shares having face value Rs. 2/- each.
- The Board of Directors of the company has recommended a dividend of Rs. 0.50 per equity share for the financial year ended on 31st March, 2026. The Dividend will be paid after approval of the same by shareholders in the ensuing Annual General meeting.
- The Statutory Auditors have carried out audit of the financial results for the quarter and year ended on 31.03.2026 and have expressed an unmodified opinion in the audit report on these financial result.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED


NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place : Delhi
Dated : 30.05.2026

TITAN BIOTECH LIMITED
Standalone Balance Sheet as at 31st March, 2026

(Rs. in Lakhs.)

Particulars	As at	
	31/03/2026 Audited	31/03/2025 Audited
I. ASSETS		
I. Non-Current Assets		
a. Property, Plant and Equipment	5,133.97	4,828.88
b. Capital Work-in-Progress	172.73	168.38
c. Right of use Assets	1,018.48	887.33
d. Intangible assets	8.39	10.61
e. Intangible assets under development	-	1.60
f. Financial Assets		
(i) Investments	4,965.67	2,449.99
(ii) Other Financial Assets	483.01	328.10
g. Other non-current assets	11.38	18.03
Total Non-current assets	11,793.63	8,692.92
2. Current Assets		
a. Inventories	5,576.91	5,082.06
b. Financial Assets		
(i) Trade receivables	2,282.86	1,881.63
(ii) Cash and cash equivalents	147.77	512.79
(iii) Bank balances other than (ii) above	39.56	43.04
c. Current Tax Assets (Net)	-	7.31
d. Other Current Assets	477.15	424.04
Total Current assets	8,524.25	7,950.87
TOTAL ASSETS	20,317.88	16,643.79
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	16,257.78	13,686.99
TOTAL EQUITY	17,084.15	14,513.36
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	32.67	18.43
(ii) Lease liabilities	144.33	23.48
b. Provisions	227.90	162.78
c. Deferred tax liabilities (Net)	232.56	152.10
Total Non-Current Liabilities	637.46	356.79
2. Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	334.40	191.79
(ii) Lease liabilities	59.32	45.97
(iii) Trade payables		
(a) Total outstanding dues of micro enterprise and small enterprises	215.11	55.03
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	638.99	710.49
(iv) Other financial liabilities	437.49	380.20
b. Other current liabilities	697.48	326.82
c. Provisions	86.87	63.34
d. Current Tax Liabilities (Net)	126.61	-
Total Current Liabilities	2,596.27	1,773.64
TOTAL EQUITY AND LIABILITIES	20,317.88	16,643.79

For Titan Biotech Limited


 [Naresh Kumar Singla]

Managing Director

DIN-00027448

Place : Delhi

Dated : 30.05.2026



TITAN BIOTECH LIMITED
Standalone Cash Flow Statement for the year ended on 31st March, 2026

(Rs. in Lakhs.)

Particulars	Year ended	Year ended
	31/03/2026 Audited	31/03/2025 Audited
A. CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before Tax	3,817.45	2,436.73
Adjustment for :		
Finance Costs	91.39	80.18
Provision for employee benefits	76.47	31.91
Earlier year Taxes	-	(0.30)
Unrealised foreign exchange differences	22.46	0.38
Provision for expected credit losses of trade receivables	36.26	-
Depreciation and Amortization Expenses	492.53	416.98
Operating profit before working capital changes	4,536.56	2,965.88
Changes in working Capital:		
(Increase) in Inventories	(494.85)	(515.18)
(Increase)/ Decrease in trade receivables	(460.00)	(9.53)
(Increase)/ Decrease in other financial assets	(148.27)	(228.34)
(Increase)/ Decrease in other current assets	(53.12)	118.89
Increase/ (Decrease) in trade payables	88.64	184.77
Increase/ (Decrease) in other financial liabilities	57.28	13.62
Increase/ (Decrease) in other current liabilities	370.67	81.17
Cash generation from operation	3,896.91	2,611.28
Less: Income tax paid	(854.83)	(598.95)
Net Cash generated/ (used) - Operating Activities	3,042.08	2,012.33
B. CASH FLOWS FROM INVESTMENT ACTIVITIES		
Investments in debt instruments quoted and unquoted equity instruments	(2,515.67)	(131.66)
Purchase of property, plant and equipment	(740.09)	(936.88)
Proceeds from sale of property, plant & equipment	0.43	1.58
Addition of capital work in progress (net)	(4.34)	84.83
Purchase of other intangible assets	-	(5.39)
Purchase of intangible assets under development	1.60	0.68
(Addition) in right of use assets	(186.90)	(2.13)
Proceeds from/(investment in) bank deposits	3.48	1.50
Net Cash Generated/ (Used) - Investing Activities	(3,441.49)	(987.47)
C. CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	14.25	(26.91)
Repayment of Lease Liabilities	134.19	(43.75)
Proceeds/(Repayment) of Short-term Borrowings (Net)	142.61	(479.97)
Finance Cost paid	(91.39)	(80.18)
Dividend paid	(165.27)	(165.27)
Net cash (used) - financing activities	34.39	(796.08)
Net (Decrease) in Cash and Cash Equivalents	(365.02)	228.78
Cash and cash equivalents at the beginning of the year	512.79	284.01
Cash and cash equivalents at the end of the year	147.77	512.79
Balance with banks	139.43	504.93
Cash on hand	8.34	7.86
Bank deposits with original maturity less than 3 months	-	-
Cash and cash equivalents as per Standalone Statement of Cash Flows	147.77	512.79

Notes:

- The above Standalone Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.
- Figures in bracket represent outflows.
- Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

For Titan Biotech Limited


[Naresh Kumar Singla]
Managing Director
DIN-00027448

Place : Delhi
Dated : 30.05.2026





Independent Auditor's Review Report on Quarterly and year to date audited Consolidated Financial Results of Titan Biotech Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

TO THE BOARD OF DIRECTORS OF TITAN BIOTECH LIMITED

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Titan Biotech Limited (hereinafter referred to as the "Holding Company") and its share of the net profit after tax and total comprehensive income and its associate for the year ended March 31, 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate consolidated audited financial statements /financial information of the Associate, the aforesaid consolidated annual financial results:

- i. include the annual financial results of the following: Peptech Biosciences Limited (Associate), Titan Media Limited (Associate)
- ii. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- iii. Give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter and year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results section of our report. We are independent of the Group, its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, along with the consideration of reports of the other auditors referred to in paragraph (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.



Management's Responsibilities for the Consolidated Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit and other comprehensive income and other financial information of the Group including its associate in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the Companies included in the Group and the respective Management and Board of Directors, of its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the Companies included in the Group and the respective Management and Board of Directors, of its associate are responsible for assessing the ability of each Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies included in the Group and the respective Management and Board of Directors, of its associate is responsible for overseeing the financial reporting process of each Company.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the group has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate and to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the consolidated financial statements / consolidated financial information of the entities within the Group and its associate to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of consolidated financial statements / consolidated financial information of such entities included in the consolidated annual financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in paragraph (a) of the Other Matters paragraph in this audit report.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matter

- a) The consolidated audited annual financial results include the Group's share of total net profit after tax of Rs. 243.80 lakh and total comprehensive income of Rs. (0.17) lakh for the year ended March 31, 2026, as considered in the consolidated annual financial results, in respect of 2 associates. These audited financial statements/ financial information have been audited/reviewed by us.
- b) The consolidated annual financial results include the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For A N S K & Associates,
Chartered Accountants
FRN - 026177N

AKHIL Digitally signed
by AKHIL MITTAL
Date: 2026.05.30
13:48:14 +05'30'
MITTAL

(CA Akhil Mittal)

Partner

Membership No. –517856

UDIN: 26517856TPARYI6324

Date: May 30, 2026

Place: Delhi

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011-71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2026

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	CONSOLIDATED				
		QUARTER ENDED			YEAR ENDED	YEAR ENDED
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
	AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED	
1	INCOME					
	Revenue from operations	4,883.35	5,650.57	3,516.93	20,619.03	15,645.08
	Other income	210.64	125.71	138.07	541.02	391.25
	Total income	5,093.99	5,776.28	3,655.00	21,160.05	16,036.33
2	EXPENSES					
	Cost of materials consumed	2,590.68	2,727.66	1,730.44	9,916.35	7,548.08
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(707.75)	9.12	(229.18)	(296.82)	(285.27)
	Employee benefits expense	943.53	853.09	694.39	3,236.20	2,637.96
	Finance costs	23.72	25.74	7.88	91.39	80.18
	Depreciation and amortization expense	129.75	126.63	84.33	492.53	416.98
	Other expenses	1,085.89	977.83	864.29	3,902.95	3,201.67
	Total expenses	4,065.82	4,720.07	3,152.15	17,342.60	13,599.60
3	Profit before exceptional items and tax (1-2)	1,028.17	1,056.21	502.85	3,817.45	2,436.73
4	Exceptional items	-	-	-	-	-
5	Profit before tax (3+4)	1,028.17	1,056.21	502.85	3,817.45	2,436.73
6	Tax expense					
	(I) Current tax	302.22	262.69	124.68	988.74	596.92
	(II) Deferred tax	70.38	6.70	1.56	83.99	12.40
	(III) Earlier year taxes	-	-	-	-	0.30
	Total tax (I+II+III)	372.60	269.39	126.24	1,072.73	609.62
7	Profit for the period (5-6)	655.57	786.82	376.61	2,744.72	1,827.11
8	Share in profit of associate	17.34	66.04	28.07	243.80	326.05
9	Profit for the period (7+8)	672.91	852.86	404.68	2,988.52	2,153.16
10	Other comprehensive income					
	(i) Items that will not be reclassified to profit or loss					
A	(ia) Re-measurement gain on defined benefit plans	(19.51)	2.44	(7.76)	(12.19)	9.76
	(ii) Income tax on the above item	5.38	(0.61)	1.95	3.54	(2.46)
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax on the above item	-	-	-	-	-
	Share in other comprehensive income of associate	(0.17)	-	-	(0.17)	-
	Total other comprehensive income for the period (A+B) (net of taxes)	(14.30)	1.83	(5.81)	(8.82)	7.30
11	Total comprehensive income for the period (7+8)	658.61	854.69	398.87	2,979.70	2,160.46
12	Net profit attributable to:					
	Owners of the holding company					
	Non-controlling interest					
13	Other comprehensive income attributable to:					
	Owners of the holding company					
	Non-controlling interest					
14	Total comprehensive income attributable to (10+11)					
	Owners of the holding company					
	Non-controlling interest					
15	Paid-up equity share capital (face value of Rs. 2/- each)	826.37	826.37	826.37	826.37	826.37
16	Other Equity				17,328.38	14,513.95
17	Earnings per equity share (face value of Rs. 2/- each) not annualised					
	(1) Basic	1.63	2.06	0.98	7.23	5.21
	(2) Diluted	1.63	2.06	0.98	7.23	5.21

Notes:

- The above consolidated audited financial results for the quarter and year ended on 31.03.2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on May 30, 2026. The statutory auditors of the company have carried out a limited review of the aforesaid results. The results for the quarter and year ended March 31, 2026, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- The consolidated audited financial results for the quarter and year ended on 31.03.2026 include the results of following -
Associate Companies - Peptech Biosciences Limited and Titan Media Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019 Accordingly, the Company has recognized provision for income tax for the quarter and year ended March 31, 2026 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated audited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.
- During the year, the company paid Rs. 56.50 Lakhs towards Corporate Social Responsibility (CSR) expenditure.
- The subdivision of Equity Shares was made effective from 20th February, 2026, being the record date fixed for the subdivision of Equity Shares from existing Rs. 10/- per share to Rs. 2 per share in the ratio of 1:5. Consequently, the paid-up share capital of the company stands altered from 82,63,700 Equity Shares having a face value of Rs. 10/- each to 4,13,18,500 Equity Shares having face value Rs. 2/- each.
- The Board of Directors of the company has recommended a dividend of Rs. 0.50 per equity share for the financial year ended on 31st March, 2026. The Dividend will be paid after approval of the same by shareholders in the ensuing Annual General meeting.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place: Delhi
Dated: 30.05.2026

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RTICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011-71239900, Email : kr@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2026

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	CONSOLIDATED				
		QUARTER ENDED			YEAR ENDED	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
	AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED	
1	Total income from operations (Net)	5,093.99	5,776.28	3,655.00	21,160.05	16,036.33
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	1,028.17	1,056.21	502.85	3,817.45	2,436.73
3	Net profit for the period before tax (after exceptional and/or extraordinary items)	1,028.17	1,056.21	502.85	3,817.45	2,436.73
4	Net profit for the period after tax (after exceptional and/or extraordinary items)	672.91	852.86	404.68	2,988.52	2,153.16
5	Total comprehensive income for the period (comprising Profit for the period(after tax) and other comprehensive income(after tax)(refer note 3)	658.61	854.69	398.87	2,979.70	2,160.46
6	Paid-up equity share capital (face value of Rs. 2/- per share)	826.37	826.37	826.37	826.37	826.37
7	Other equity excluding revaluation reserves as per the balance sheet	-	-	-	17,328.38	14,513.95
8	Earnings per share (of INR 2/- each)					
	(a) Basic	1.63	2.06	0.98	7.23	5.21
	(b) Diluted	1.63	2.06	0.98	7.23	5.21


NOTES :

- The above is an extract of the detailed format of consolidated audited Financial Results for the quarter and year ended on 31.03.2026 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated audited Financial Results for the said quarter and year ended on 31st March 2026 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above consolidated audited financial results for the quarter and year ended on 31.03.2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on May 30, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31.03.2026 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The consolidated audited financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.
- During the year, the company paid Rs. 56.50 Lakhs towards Corporate Social Responsibility (CSR) expenditure.
- The subdivision of Equity Shares was made effective from 20th February, 2026, being the record date fixed for the subdivision of Equity Shares from existing Rs. 10/- per share to Rs. 2 per share in the ratio of 1:5. Consequently, the paid-up share capital of the company stands altered from 82,63,700 Equity Shares having a face value of Rs. 10/- each to 4,13,18,500 Equity Shares having face value Rs. 2/- each.
- The Board of Directors of the company has recommended a dividend of Rs. 0.50 per equity share for the financial year ended on 31st March, 2026. The Dividend will be paid after approval of the same by shareholders in the ensuing Annual General Meeting.

Place : Delhi
Dated : 30.05.2026

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448




TITAN BIOTECH LIMITED
Consolidated Balance Sheet as at 31st March, 2026

(Rs. in Lakhs.)

Particulars	As at	
	31/03/2026 Audited	31/03/2025 Audited
I. ASSETS		
1. Non-Current Assets		
a. Property, Plant and Equipment	5,133.97	4,828.88
b. Capital Work-in-Progress	172.73	168.38
c. Right of use Assets	1,018.48	887.33
d. Intangible assets	8.39	10.61
e. Intangible assets under development	-	1.60
f. Financial Assets		
(i) Investments	6,036.27	3,276.95
(ii) Other Financial Assets	483.01	328.10
g. Other non-current assets	11.38	18.03
Total Non-current assets	12,864.23	9,519.88
2. Current Assets		
a. Inventories	5,576.91	5,082.06
b. Financial Assets		
(i) Trade receivables	2,282.86	1,881.63
(ii) Cash and cash equivalents	147.77	512.79
(iii) Bank balances other than (ii) above	39.56	43.04
c. Current Tax Assets (Net)	-	7.31
d. Other Current Assets	477.15	424.04
Total Current assets	8,524.25	7,950.87
TOTAL ASSETS	21,388.48	17,470.75
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	17,328.38	14,513.95
TOTAL EQUITY	18,154.75	15,340.32
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	32.67	18.43
(ii) Lease liabilities	144.33	23.48
c. Provisions	227.90	162.78
b. Deferred tax liabilities (Net)	232.56	152.10
Total Non-Current Liabilities	637.46	356.79
2. Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	334.40	191.79
(ii) Lease liabilities	59.32	45.97
(iii) Trade payables		
(a) Total outstanding dues of micro enterprise and small enterprises	215.11	55.03
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	638.99	710.49
(iv) Other Financial Liabilities	437.49	380.20
b. Other current liabilities	697.48	326.82
c. Provisions	86.87	63.34
d. Current Tax Liabilities (Net)	126.61	-
Total Current Liabilities	2,596.27	1,773.64
TOTAL EQUITY AND LIABILITIES	21,388.48	17,470.75

For Titan Biotech Limited


[Naresh Kumar Singla]
Managing Director
DIN-00027448



Place : Delhi
Dated : 30.05.2026

TITAN BIOTECH LIMITED
Consolidated Cash Flow Statement for the year ended on 31st March, 2026

(Rs. in Lakhs.)

Particulars	Year ended	Year ended
	31/03/2026 Audited	31/03/2025 Audited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before Tax	3,817.45	2,436.73
Adjustment for :		
Finance Costs	91.39	80.18
Provision for employee benefits	76.47	31.91
Earlier year Taxes	-	(0.30)
Unrealised foreign exchange differences	22.46	0.38
Provision for expected credit losses of trade receivables	36.26	-
Depreciation and Amortization Expenses	492.53	416.98
Operating profit before working capital changes	4,536.56	2,965.88
Changes in working Capital:		
(Increase) in Inventories	(494.85)	(515.18)
(Increase)/ Decrease in trade receivables	(460.00)	(9.53)
(Increase)/ Decrease in other financial assets	(148.27)	(228.34)
(Increase)/ Decrease in other current assets	(53.12)	118.89
Increase/ (Decrease) in trade payables	88.64	184.77
Increase/ (Decrease) in other financial liabilities	57.28	13.62
Increase/ (Decrease) in other current liabilities	370.67	81.17
Cash generation from Operation	3,896.91	2,611.28
Payment of Direct Taxes	(854.83)	(598.95)
Net Cash generated/ (used) - Operating Activities	3,042.08	2,012.33
B. CASH FLOW FROM INVESTMENT ACTIVITIES		
Investments in debt instruments quoted and unquoted equity instruments	(2,515.67)	(131.66)
Purchase of property, plant and equipment	(740.09)	(936.88)
Proceeds from sale of property, plant & equipment	0.43	1.58
Addition of capital work in progress (net)	(4.34)	84.83
Purchase of other intangible assets	-	(5.39)
Purchase of intangible assets under development	1.60	0.68
(Addition) in right of use assets	(186.90)	(2.13)
Proceeds from/(investment in) bank deposits	3.48	1.50
Net Cash Generated/ (Used) - Investing Activities	(3,441.49)	(987.47)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	14.25	(26.91)
Repayment of Lease Liabilities	134.19	(43.75)
Proceeds/(Rapyment)of Short-term Borrowings(Net)	142.61	(479.97)
Finance Cost paid	(91.39)	(80.18)
Dividend paid	(165.27)	(165.27)
Net cash (used) - financing activities	34.39	(796.08)
Net (Decrease) in Cash and Cash Equivalents	(365.02)	228.78
Cash and cash equivalents at the beginning of the year	512.79	284.01
Cash and cash equivalents at the end of the year	147.77	512.79
Balance with banks	139.43	504.93
Cash on hand	8.34	7.86
Bank deposits with original maturity less than 3 months	-	-
Cash and cash equivalents as per Standalone Statement of Cash Flows	147.77	512.79


Notes:

- The above Consolidated Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.
- Figures in bracket represent outflows.
- Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

For Titan Biotech Limited



[Naresh Kumar Singla]
Managing Director
DIN-00027448



Place : Delhi
Dated : 30.05.2026